Abstract: Embodiments relate to the discovery that certain tripeptide amides and glycine amide can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising said tripeptide amides and/or glycine amide and methods of using said compounds for the prevention and treatment of viral infection, such as HIV infection, are provided.

Abstract: Embodiments relate to the discovery that tripeptide amides, which correspond to viral capsid sequences, can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising tripeptide amides and methods of using said compounds for the prevention and treatment of viral infection, such as HIV infection, are provided.

Abstract: Embodiments relate to the discovery that tripeptide amides, which correspond to viral capsid sequences, can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising tripeptide amides and methods of using said compounds for the prevention and treatment of viral infection, such as HIV infection, are provided.

Abstract: The present invention relates to the discovery that a specific pentamer peptide amide, which corresponds to a viral capsid sequence, can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising said pentamer peptide amide and methods of using said compounds for the prevention and treatment of viral infection, such as HIV infection, are provided.

Abstract: The present invention is related to the discovery of peptides that modulate the protein-protein interactions necessary for protein polymerization and the assembly of supramolecular protein complexes. More specifically, biotechnological tools and medicaments comprising various small peptides that have a modified carboxyl terminus are disclosed for use in the study and treatment or prevention of human disease.

Abstract: The present invention relates to the discovery that a specific pentamer peptide amide, which corresponds to a viral capsid sequence, can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising said pentamer peptide amide and methods of using said compounds for the prevention and treatment of viral infection, such as HIV infection, are provided.

Abstract: The present invention relates to the discovery that a specific pentamer peptide amide, ALGPG-NH2, which corresponds to a viral capsid sequence, can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising said pentamer peptide amide and methods of using said compounds for the prevention and treatment of viral infection, such as HIV infection, are provided.

Abstract: The discovery of peptides in amide form that inhibit viral infection, including human immunodeficiency virus (HIV) infection is disclosed. Methods of use of peptides are also disclosed including use in medicaments for the treatment and prevention of viral infection, such as HIV infection.

Abstract: The discovery of peptides in amide form that inhibit viral infection, including human immunodeficiency virus (HIV) infection is disclosed. Methods of use of peptides are also disclosed including use in medicaments for the treatment and prevention of viral infection, such as HIV infection.

Abstract: Novel peptides are disclosed which correspond to epitopes of the HIV-1 gp120 protein. These antigenic peptides induce antibody-dependent cellular cytotoxicity against HIV, and thus are useful in immunization against HIV infection and induction of a heightened immune response to HIV.

Abstract: Peptides corresponding to epitopes of HTLV-2 proteins are provided. These peptides are immunologically reactive with HTLV-2 specific antibodies. Several of the peptides are sufficiently unreactive to antibodies to HTLV-1 to distinguish between antibodies which recognize HTLV-1 and those which recognize HTLV-2. Thus HTLV-1 infections can be distinguished from HTLV-2 infections. The peptides are useful in assays for detection of HTLV-2 infection or exposure. The peptides are also useful as vaccine compositions against HTLV-2. Antibodies generated in response to immunization by the peptides are also provided.

Abstract: It has now been found that relatively short peptides such as the tripeptide glycyl-prolyl-glycine are able to effectively inhibit HIV infection of cells and syncytia formation between HIV infected and and non-infected cells. The peptides are suitable for therapy of patients infected with HIV and in prevention of HIV infection.

Abstract: In accordance with the present invention, novel peptides corresponding to epitopes of human immunodeficiency virus-1 gp120 protein and analogues and homologs thereof are provided. These peptides can be utilized alone or in combination, uncoupled or coupled to other molecules or substrates. The peptides are useful in immunization against human immunodeficiency virus infection and in production of polyclonal and monoclonal antibodies.

Abstract: Peptides corresponding to regions of the human immunodeficiency virus protein gp-120 are provided for eliciting T-cell activation.

Abstract: Peptides corresponding to epitopes of HTLV-2 proteins are provided. These peptides are immunologically reactive with HTLV-2 specific antibodies. Several of the peptides are sufficiently unreactive to antibodies to HTLV-1 to distinguish between antibodies which recognize HTLV-1 and those which recognize HTLV-2. Thus HTLV-1 infections can be distinguished from HTLV-2 infections. The peptides are useful in assays for detection of HTLV-2 infection or exposure. The peptides are also useful as vaccine compositions against HTLV-2. Antibodies generated in response to immunization by the peptides are also provided.

Abstract: Four peptides corresponding to regions of the glycoprotein encoded by the env gene of HTLV1 are provided. These peptides which are immunologically reactive with HTLV-1 specific antibodies are useful in assays for detection of HTLV-1 infection or exposure and in compositions to elicit the production of antibodies against HTLV-1 in animals and man.

Abstract: A synthetic peptide antigen corresponding to a region of the glycoprotein gp41 encoded by the env gene of HIV-2 is provided. The peptide which is immunologically reactive with HIV-2 specific antibodies is useful in assays for detection of HIV-2 infection or exposure and in compositions to elicit the production of antibodies against HIV-2 in animals including man.